US FDA’s co-crystal final guidance to reduce cGMP burden

By Flora Southey contact

- Last updated on GMT


Related tags: New drug application, Food and drug administration

In response to stakeholder feedback, the US FDA has issued a final guidance detailing changes to the regulatory classification of co-crystals, from intermediate to API.

The US Food and Drug Administration (FDA) released the Regulatory classification of pharmaceutical co-crystals guidance​ this month, following its introduction in April 2013, and a revised draft​ in August 2016.

In the final guidance, the Agency advises new drug application (NDA) and abbreviated new drug application (ANDA) applicants that a co-crystal API meeting the guidance criteria will no longer be considered a drug product intermediate, but an API.

Pharma co-crystals

“In other words, the co-crystal form is considered in the same way as would any other morphic form of the API such as a polymorph, solvate or hydrate,” ​said the FDA.

Pharmaceutical co-crystals are composed of two or more different molecules, typically an active pharmaceutical ingredient (API) and an excipient.

In theory, the non-API component of a co-crystal can be modified to enhance drug process-ability, stability or bioavailability.

According to the FDA, “Pharmaceutical co-crystals have provided opportunities for engineering solid-state forms beyond conventional solid-state forms of an API, such as salts and polymorphs.

“Another advantage of co-crystals is that they generate a diverse array of solid-state forms for APIs that lack ionisable functional groups, which is a prerequisite for salt formation.”

Stakeholder feedback

The reclassification responds to stakeholder feedback, requesting the Agency clarify the appropriate classification of co-crystals and the regulatory consequences of such classifications.

In August, 2016 in-PharmaTechnologist reported​ drugmakers were reluctant to work with pharmaceutical co-crystals due to their classification as ‘intermediates’ – which require stricter manufacturing practices in the drug making process than solvates.

“In a commercial setting, co-crystals are typically manufactured in drug substance facilities. However, when classified as a drug product intermediate, additional current good manufacturing practice requirements (cGMPs) apply to co-crystals,” ​said the FDA at the time.

Related news

Show more

Related products

show more

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Related suppliers

Follow us


View more